Healthcare / Drug Manufacturers - Specialty & GenericBSE
$21.49
+0.31 (+1.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $4.5M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$109M
P/E
716.3x
↑EV/EBITDA
5.4x
↓ROE
6.1%
↑Gross Margin
30.1%
↓Debt/Equity
0.43
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.2%
FCF CAGR
—
FCF margin
2.2%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $209.4M · net income $5.8M · FCF $4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $209.4M | $209.4M | $264.5M | $266.9M | $144.5M |
| Net Income | $5.8M | $5.8M | $7.7M | $7.7M | $-6.6M |
| EBITDA | $26.3M | $26.3M | $26.6M | $22.2M | $5.6M |
| EPS | 1.14 | 1.14 | 1.52 | 1.51 | -1.30 |
| Gross Margin | 30.1% | 30.1% | 32.8% | 30.4% | 27.9% |
| Operating Margin | 1.2% | 1.2% | 4.5% | 4.5% | -4.5% |
| Net Margin | 2.8% | 2.8% | 2.9% | 2.9% | -4.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.43 | 0.43 | 0.57 | 0.56 | 0.73 |
| Cash Flow | |||||
| Free Cash Flow | $4.5M | $4.5M | $-5.3M | $8.3M | $-8.8M |
| Returns | |||||
| ROE | 6.1% | 6.1% | 8.6% | 9.5% | -9.0% |
| Valuation | |||||
| P/E | 716.33 | 716.33 | 23.84 | 8.77 | — |
| EV/EBITDA | 5.38 | 5.38 | 8.78 | 4.95 | 18.58 |
| P/B | 1.15 | 1.15 | 2.06 | 0.83 | 0.73 |
| Growth & Yield | |||||
| Revenue Growth | -20.8% | -20.8% | -0.9% | 84.6% | — |
| EPS Growth | -25.0% | -25.0% | 0.7% | 216.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.7%
EPS terminal req.
$1.91
Spread vs growth
-43.7%
5Y implied EPS CAGR
15.1%
EPS terminal req.
$2.31
Spread vs growth
-40.1%
10Y implied EPS CAGR
12.5%
EPS terminal req.
$3.72
Spread vs growth
-37.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.6%
Start / end P/E
12.6x → 18.9x
EPS bridge
1.52 → 1.14
Residual
-12.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.